Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Kazia Therapeutics Limited - news published 150 - readings 1.737

BACK

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the "Prospectus ...

31.03.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the "Prospec ...

31.03.2025

Kazia Therapeutics Limited

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil (Form 6-K)

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil Sydney, March 31, 2025 - Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug ...

31.03.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the "Prospec ...

31.03.2025

Kazia Therapeutics Limited

Current Report by Foreign Issuer (Form 6-K)

Exhibit 99.1 2024 ANNUAL REPORT Contents 2 4 6 Chairman and Key About GBM CEO's Letter Milestones 8 12 Environment, Financial Society & Reports Governance ii ASX:KZA | NASDAQ:KZIA Chairman and CEO's The journey of a young biotech Letter company is often circuitous, but we have nevertheless continued to make great progress in the past year. We Key have two first-class drug ...

13.03.2025

Kazia Therapeutics Limited

2024 Annual Report

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Kazia Therapeutics Limited published this content on March 11, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on March 11, 2025 at 03:05:31.683 .

11.03.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

21.02.2025

Kazia Therapeutics Limited

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease (Form 6-K)

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease Sydney, February 20, 2025 - Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced ...

20.02.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

20.02.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

20.02.2025

Kazia Therapeutics Limited

Notice of Effectiveness (Form EFFECT)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: February 5, 2025 4:00 P.M. Form: F-1 CIK: 0001075880 Company Name: KAZIA THERAPEUTICS LTD File Number: 333-284606 Attachments Original document Permalink Disclaimer Kazia Therapeutics Limited published this content on February 05, 2025 , and is solely responsible ...

06.02.2025

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS 1,373,333 American Depositary Shares Representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 1,373,333 American Depositary Shares, or the Offer ...

05.02.2025

Kazia Therapeutics Limited

Current Report by Foreign Issuer (Form 6-K)

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Kazia Therapeutics Limited published this content on February 03, 2025 , and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on February 03, 2025 at 13:37:13.086 .

03.02.2025

Kazia Therapeutics Limited

Kazia Corporate Presentation January 2025

A Diversified Oncology Drug Development Company Kazia Corporate Overview January 2025 NASDAQ: KZIA | X: @KaziaTx Company Overview A late-clinical-stage oncology drug development company Paxalisib EVT801 Corporate Highlights Licensing-driven business model focused on high quality, differentiated clinical- stage assets sourced from Genentech Brain-penetrant pan-PI3K / mTOR inhib ...

03.02.2025

Kazia Therapeutics Limited

Registration Statement by Foreign Issuer (Form F-1)

F-1 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KAZIA THERAPEUTICS LIMITED (Exact name of Registrant as specified in its charter) Australia 2834 Not applicable (Sta ...

30.01.2025

Kazia Therapeutics Limited - news published 150 - readings 1.737

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil (Form 6-K)

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Current Report by Foreign Issuer (Form 6-K)

Kazia Therapeutics Limited

2024 Annual Report

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease (Form 6-K)

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Notice of Effectiveness (Form EFFECT)

Kazia Therapeutics Limited

Supplemental Prospectus (Form 424B3)

Kazia Therapeutics Limited

Current Report by Foreign Issuer (Form 6-K)

Kazia Therapeutics Limited

Kazia Corporate Presentation January 2025

Kazia Therapeutics Limited

Registration Statement by Foreign Issuer (Form F-1)

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member